Biosign announces successful completion of Glucometry Trial

    TORONTO, March 13 /CNW/ - Biosign Technologies Inc. (CNQ: BIOS) announces
today the successful completion of GAMUT-1 glucometry trial.
    The trial assessed the substantial equivalence of UFIT(TM), a noninvasive
technology, with the laboratory glucose measurement and a top-brand glucose
meter ("test strip glucometer") that requires patients to draw blood. The
results are scheduled for presentation at an international workshop on medical
measurement and applications, organized by the Institute of Electrical and
Electronics Engineers (IEEE) on May 4th, 2007.
    Biosign will integrate this novel feature into existing UFIT(TM)
monitoring capabilities, according to local market conditions. The plan will
be informed by feedback from another track of the GAMUT study, which is
evaluating the reliability and utility of UFIT(TM) noninvasive measurements
for routine health monitoring and therapy evaluation.

    About Biosign

    Biosign develops technologies, products and initiatives to address
critical problems in global health care. The focus is on measuring health
status, outcomes, and risk toward maximizing clinical awareness, readiness,
and effectiveness. The thrust is on enabling autonomous medical care in a way
that optimizes quality, access, and cost. The core technology expands virtual
instrumentation by adding universal measurement and rapid knowledge formation
to support service oriented enterprising across global markets. Trademarked
UFIT, the web-based technology powers several business lines in adaptive
clinical trials, self-care, medical homes, distributed diagnostics and home
health care. Regulated applications of UFIT(TM) include intelligent systems
for noninvasive monitoring at the point of care which are useful in optimizing
health and managing chronic diseases such as hypertension and diabetes.

    Forward-Looking Statements

    This press release contains forward looking statements. Forward looking
    statements are not based on historical facts, but rather on current
    expectations, Company assumptions and projections about future events,
    and are therefore subject to risks and uncertainties which could cause
    actual results to differ materially from the future results expressed or
    implied by the forward looking statements. Such statements are qualified
    in their entirety by the inherent risks and uncertainties surrounding
    future expectations. Company assumptions and risk factors are listed from
    time to time in Biosign's reports, public disclosure documents including
    Management's Discussion and Analysis, Management Information Circular,
    and in other filings with stock exchanges and securities regulatory
    authorities in Canada.

    You should not place undue importance on forward-looking statements and
    should not rely upon this information as of any other date. While Biosign
    may elect to, Biosign is under no obligation and does not undertake to
    update this information at any particular time. This press release was
    prepared by management from information available to March 13, 2007.
    %SEDAR: 00014068E

For further information:

For further information: Richard Potts, Chairman & CEO, Phone: (416)
218-9800 ext. 234, Email:

Organization Profile

Biosign Technologies Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890